Remaster SPMS Study in Phoenix, Arizona
ARIZONA NEUROSCIENCE RESEARCH · PHOENIX
Arizona Neuroscience Research (ANR) is preparing to enroll participants in Remaster (CLOU064P12301), a Phase 3 clinical trial for adults with secondary progressive multiple sclerosis (SPMS). Contact our Phoenix research team to confirm local availability and screening requirements.
Contact the Remaster study team or call (480) 210-8723.
What is the Remaster study?
This Novartis-sponsored study evaluates the efficacy and safety of remibrutinib in SPMS. It is a randomized, double-blind, placebo-controlled Phase 3 trial. Participation does not guarantee a health benefit.
Who may be eligible?
The sponsor’s public listing describes adults ages 18–65 with SPMS. Additional requirements apply, and the research team must assess eligibility. Contact ANR for current criteria and approved study information.
Is ANR enrolling now?
ANR’s website currently lists Remaster as an upcoming enrolling study. Overall trial recruitment status may differ from availability at an individual location. Ask the team about the current Phoenix screening schedule before planning a visit.
Questions to ask the Phoenix study team
- Is screening available at ANR, and which location would I visit?
- What records are needed to discuss eligibility?
- What visits, assessments and time commitments are involved?
- What are the potential risks, alternatives and costs?
- How does the study coordinate with my usual neurology care?
Official study information
Study identifiers: CLOU064P12301 and NCT07225504. Sponsor: Novartis.
Contact Arizona Neuroscience Research
ANR serves prospective research volunteers in Phoenix, Arizona. Confirm the correct visit location directly with the team. Contact and location information.
Clinical trial FAQs · Meet ANR · Request study information